Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Immune Checkpoint Inhibitors

Phase 2Small molecule

PPeking Union Medical College Hospital

Immune Checkpoint Inhibitors is one of 155 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 2.

6

Indications

16

Total Trials

12

Active Trials

154

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaActive, not recruiting

Esophageal CarcinomaActive, not recruiting

Autoimmune DiseaseActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Gastric CancerActive, not recruiting

Esophageal Squamous Cell CarcinomaPreclinical

Active, not recruiting

Esophageal CarcinomaPhase 1/Phase 2

Active, not recruiting

Autoimmune DiseasePreclinical

Active, not recruiting

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Immune Checkpoint Inhibitors

PPeking Union Medical College Hospital

Gemzar

GGynecologic Oncology Group

PORTRAZZA

Lenvima

Vizimpro

Gilotrif

Boehringer Ingelheim

Ofev

Boehringer Ingelheim

PD-1 Inhibitor

Johnson & Johnson

Tyrosine Kinase Inhibitor

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Immune Checkpoint Inhibitors

NCT06408688

Autoimmune Disease

NCT07249060

Phase 1/2Recruiting

Esophageal Carcinoma

NCT05937438

N/ANot yet recruiting

Esophageal Squamous Cell Carcinoma

NCT07067450

Q4 2027

Phase 2Recruiting

Gastric Cancer

NCT06685887

Q1 2028

Phase 2Not yet recruiting

Malignant Tumors

NCT07277777

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Sarcopenia and CRP-TyG Index (CTI) as Predictors of Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer

Completed·—··NCT07192926·131 enrolled

A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.

Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT07271602·104 enrolled

Immune Checkpoint Inhibitors2 trials

Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors

Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 4·NCT06408688·100 enrolled

HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC

Active, not recruiting·FFirst Hospital of China Medical University··NCT06632106·97 enrolled

Immunotherapy2 trials

Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy

Unknown status·PPeking Union Medical College Hospital·Phase 1/2·NCT06074029·50 enrolled

Application of mRNA Immunotherapy Technology in EB Virus Related Diseases

Not yet recruiting·XXinqiao Hospital of Chongqing·Phase 1·NCT07349836·40 enrolled

Esophageal Squamous Cell Carcinoma2 trials

Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study

Not yet recruiting·—·Phase 1·NCT07034118·23 enrolled

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

Not yet recruiting·SSichuan University·N/A·NCT07067450·98 enrolled

Treatment1 trial

HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure

Unknown status·TThe Central Hospital of Lishui City·N/A·NCT05233358·176 enrolled

7 more indications

Survival1 trial

Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients

Active, not recruiting·SSeoul National University··NCT06751108·2,000 enrolled

Gastric Cancer1 trial

A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06685887·34 enrolled

Malignant Tumors1 trial

125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors

Not yet recruiting·LLi Min·Phase 2·NCT07277777·90 enrolled

Injury1 trial

Assessment of Myocardial Injury in Patients Treated With Immune Checkpoint Inhibitors

Unknown status·FFlinders University··NCT05349058·40 enrolled

Immune-related Adverse Events1 trial

Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge

Recruiting·PPeking Union Medical College Hospital··NCT07453342·500 enrolled

Esophageal Carcinoma1 trial

Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma

Recruiting·—·Phase 1/2·NCT05937438·70 enrolled

Autoimmune Disease1 trial

Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients

Recruiting·HHospital Universitario Araba··NCT07249060·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Immune Checkpoint Inhibitors. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Immune Checkpoint Inhibitors compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Immune Checkpoint Inhibitors. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking Union Medical College Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPeking Union Medical College Hospital

Related News